Virtrial makes debut with a new platform for hybrid clinical trials

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)

Related tags: Virtual clinical trials, Telemedicine, Clinical trials, Research

Virtrial’s vision is to replace up to half of the standard clinical trial visits with virtual ones, using a hybrid approach incorporating telemedicine.

With funds from the private investment firm Kinderhook Industries, Virtrial has acquired a virtual care platform to incorporate telehealth in clinical trials. The patient management program incorporates video, text, and email, and can be used on any device.

Virtrial is not disclosing the investment amount, though it comes from the private investment firm Kinderhook Industries, which manages more than $2.0bn of committed capital.

"The technology platform we are using is already built and has been tested and proven over the past few years. Most of our investment was to acquire that technology,"​ Mark Hanley, CEO and president of Virtrial told us.

Hanley, who is the former CEO of Clinical Research Advantage (CRA) and Radiant Research founded Virtrial in 2018. The company’s vision is to replace 25-50% of standard clinical trial visits with virtual visits.

Kim Kundert also is joining the company as VP of clinical operations, having worked with Hanley at both CRA and Radiant.

Hanley in the press release said, "This is a perfect platform for post-approval trials, as patients today keep their cell phone numbers for years. Contacting them virtually in 2-5 years will be possible.”

"By utilizing a hybrid model approach to trials, we can enhance current trials by replacing a quarter to half of the visits with virtual video visits,” ​he added. “We don't plan to completely replace in-clinic visits, just maximize available resources to get results in an accurate, compliant, and timely manner."

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars